Free Trial
NASDAQ:ALEC

Alector (ALEC) Stock Price, News & Analysis

Alector logo
$1.40 -0.08 (-5.41%)
As of 04:00 PM Eastern

About Alector Stock (NASDAQ:ALEC)

Key Stats

Today's Range
$1.37
$1.49
50-Day Range
$1.03
$1.63
52-Week Range
$0.87
$6.78
Volume
679,954 shs
Average Volume
836,154 shs
Market Capitalization
$139.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Hold

Company Overview

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Alector Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

ALEC MarketRank™: 

Alector scored higher than 77% of companies evaluated by MarketBeat, and ranked 251st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alector has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 3 buy ratings, 2 hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    Alector has only been the subject of 1 research reports in the past 90 days.

  • Read more about Alector's stock forecast and price target.
  • Earnings Growth

    Earnings for Alector are expected to decrease in the coming year, from ($1.88) to ($1.98) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alector is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alector is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Alector has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Alector's valuation and earnings.
  • Percentage of Shares Shorted

    8.45% of the float of Alector has been sold short.
  • Short Interest Ratio / Days to Cover

    Alector has a short interest ratio ("days to cover") of 7.4.
  • Change versus previous month

    Short interest in Alector has recently decreased by 5.21%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Alector does not currently pay a dividend.

  • Dividend Growth

    Alector does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.45% of the float of Alector has been sold short.
  • Short Interest Ratio / Days to Cover

    Alector has a short interest ratio ("days to cover") of 7.4.
  • Change versus previous month

    Short interest in Alector has recently decreased by 5.21%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Alector has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Alector this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,440.00 in company stock.

  • Percentage Held by Insiders

    Only 9.10% of the stock of Alector is held by insiders.

  • Percentage Held by Institutions

    85.83% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Alector's insider trading history.
Receive ALEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter.

ALEC Stock News Headlines

Short Interest in Alector, Inc. (NASDAQ:ALEC) Increases By 25.1%
The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.
Alector Provides Executive Leadership Update
Alector president sells shares worth $31,974
Top Penny Stocks To Watch In May 2025
See More Headlines

ALEC Stock Analysis - Frequently Asked Questions

Alector's stock was trading at $1.89 at the beginning of 2025. Since then, ALEC stock has decreased by 25.9% and is now trading at $1.40.
View the best growth stocks for 2025 here
.

Alector, Inc. (NASDAQ:ALEC) issued its quarterly earnings results on Wednesday, February, 26th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.59. The firm earned $54.24 million during the quarter, compared to the consensus estimate of $20.41 million. Alector had a negative trailing twelve-month return on equity of 100.58% and a negative net margin of 139.74%.
Read the conference call transcript
.

The following companies are subsidiaries of Alector: Alector LLC.

Alector (ALEC) raised $177 million in an initial public offering on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.

Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alector investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Enovix (ENVX), Meta Platforms (META), Rambus (RMBS), Saia (SAIA) and Tesla (TSLA).

Company Calendar

Last Earnings
2/26/2025
Today
6/30/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALEC
Fax
N/A
Employees
270
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$10.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+175.1%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$119.05 million
Net Margins
-139.74%
Pretax Margin
-139.60%

Debt

Sales & Book Value

Annual Sales
$100.56 million
Price / Cash Flow
N/A
Book Value
$1.29 per share
Price / Book
1.13

Miscellaneous

Free Float
90,894,000
Market Cap
$145.39 million
Optionable
Optionable
Beta
0.71

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ALEC) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners